Clinical trials: Esophageal Cancer Metastatic
Esophageal Carcinoma
Study of Lobaplatin，5-Fluorouracil and Leucovorin for the Treatment of Esophageal Carcinoma
The purpose of this study is to evaluate the efficacy and the toxicity of lobaplatin, 5-fluorouracil (5-FU) and leucovorin in patients with esophageal carcinoma.
- Trial name
- NCT01034683
- Testing
- lobaplatin , 5-FU ,leucovorin
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Taian Cancer Hospital
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Esophageal Cancer, Squamous Cell
Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer
Phase II study, randomized, open-label, multicentric, willing to establish the benefit of pursuing chemotherapy beyond 6 weeks for non progressive patients.
- Trial name
- E-DIS2 (NCT03301454)
- Testing
- pursuit of chemotherapy
- Where
- 5 sites in France
- Volunteers
- 15 people
- Sponsor
- Centre Oscar Lambret
Breast Neoplasms, Colorectal Neoplasms
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor…
- Conditions
- Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
- Trial name
- OMNIRAY (NCT07114601)
- Testing
- LY4257496, Standard of Care Anticancer Therapies, LY4257529
- Where
- 33 sites in United States, Canada and 5 more
- Volunteers
- 421 people
- Sponsor
- Eli Lilly and Company
Neoplasms, Gastrointestinal Tract
LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib
This was an international multi-center trial that enrolled patients with locally advanced, unresectable, or metastatic gastric, esophageal, or gastro-esophageal junction cancer whose tumors had amplification of the ErbB2 (HER2)…
- Trial name
- NCT00680901
- Testing
- Lapatinib, Capecitabine, Oxaliplatin
- Where
- 183 sites in United States, Argentina and 21 more
- Volunteers
- 545 people
- Sponsor
- Novartis Pharmaceuticals
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Colorectal Cancer, Esophagus Cancer
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
This is a single-arm, open, dose-increasing phase I clinical study to explore the safety, tolerability and pharmacokinetic characteristics of the drug C-13-60 cells, and preliminarily observe the efficacy of the drug in CEA…
- Conditions
- Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer
- Trial name
- NCT06043466
- Testing
- CEA-targeted CAR-T cells
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Esophageal Cancer
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00030862
- Testing
- cisplatin, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach
- Trial name
- NCT02830594
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer, Cancer of the Esophagus
Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers
The investigators propose to treat patients with metastatic esophageal cancers and dysphagia with two fractions of brachytherapy followed by pembrolizumab.
- Trial name
- NCT02642809
- Testing
- Pembrolizumab, Brachytherapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT01243398
- Testing
- quality-of-life assessment
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- University of Oxford
Esophageal Neoplasms
Anlotinib Retrospective Study for Esophageal Cancer
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal…
- Trial name
- NCT05303740
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Feng Wang
Metastatic Esophageal Squamous Cell Carcinoma
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of treatment naive advanced esophageal squamous cell carcinoma patients.
- Trial name
- NCT06138028
- Testing
- TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Qingdao Central Hospital
Gastric Cancer, Gastroesophageal-junction Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal…
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Trial name
- NCT05539430
- Testing
- LB1908
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Legend Biotech USA Inc
Esophageal Neoplasms
PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy combined with immunotherapy recently.
- Trial name
- NCT06086457
- Testing
- Radiation, TP or PF regimen depended on investigator's choice., PD-1 inhibitor
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Neoplasms, Esophageal Cancer
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer.
- Conditions
- Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis
- Trial name
- RIOT3 (NCT07001592)
- Testing
- vvDD-hIL-2-RG-1
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Cancer, Esophagus Squamous Cell Carcinoma
Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of…
- Conditions
- Cancer, Esophagus Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Anal Canal Squamous Cell Carcinoma
- Trial name
- MASST (NCT03712566)
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- University Health Network, Toronto
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital